Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase®
Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Montastruc, F. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Übergeordnetes Werk: |
Enthalten in: A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier - Guan, Xiangyang ELSEVIER, 2021, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:11 ; year:2019 ; number:1 ; pages:153 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.acvdsp.2018.10.339 |
|---|
| Katalog-ID: |
ELV045296278 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045296278 | ||
| 003 | DE-627 | ||
| 005 | 20230626011026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190205s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.acvdsp.2018.10.339 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica |
| 035 | |a (DE-627)ELV045296278 | ||
| 035 | |a (ELSEVIER)S1878-6480(18)30594-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 380 |q VZ |
| 084 | |a 55.82 |2 bkl | ||
| 100 | 1 | |a Montastruc, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| 264 | 1 | |c 2019transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. | ||
| 520 | |a Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. | ||
| 700 | 1 | |a Benevent, J. |4 oth | |
| 700 | 1 | |a Rousseau, V. |4 oth | |
| 700 | 1 | |a Montastruc, G. |4 oth | |
| 700 | 1 | |a Durrieu, G. |4 oth | |
| 700 | 1 | |a Sommet, A. |4 oth | |
| 700 | 1 | |a Montastruc, J.L. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Masson |a Guan, Xiangyang ELSEVIER |t A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |d 2021 |g Amsterdam [u.a.] |w (DE-627)ELV006385559 |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:1 |g pages:153 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.acvdsp.2018.10.339 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 55.82 |j Güterverkehr |q VZ |
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 1 |h 153 | ||
| author_variant |
f m fm |
|---|---|
| matchkey_str |
montastrucfbeneventjrousseauvmontastrucg:2019----:ikfibtssoitdihttnadirtsntersoitoaipootoaiynlsssnteh |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
55.82 |
| publishDate |
2019 |
| allfields |
10.1016/j.acvdsp.2018.10.339 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica (DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 DE-627 ger DE-627 rakwb eng 380 VZ 55.82 bkl Montastruc, F. verfasserin aut Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Benevent, J. oth Rousseau, V. oth Montastruc, G. oth Durrieu, G. oth Sommet, A. oth Montastruc, J.L. oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:11 year:2019 number:1 pages:153 https://doi.org/10.1016/j.acvdsp.2018.10.339 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 11 2019 1 153 |
| spelling |
10.1016/j.acvdsp.2018.10.339 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica (DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 DE-627 ger DE-627 rakwb eng 380 VZ 55.82 bkl Montastruc, F. verfasserin aut Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Benevent, J. oth Rousseau, V. oth Montastruc, G. oth Durrieu, G. oth Sommet, A. oth Montastruc, J.L. oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:11 year:2019 number:1 pages:153 https://doi.org/10.1016/j.acvdsp.2018.10.339 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 11 2019 1 153 |
| allfields_unstemmed |
10.1016/j.acvdsp.2018.10.339 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica (DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 DE-627 ger DE-627 rakwb eng 380 VZ 55.82 bkl Montastruc, F. verfasserin aut Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Benevent, J. oth Rousseau, V. oth Montastruc, G. oth Durrieu, G. oth Sommet, A. oth Montastruc, J.L. oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:11 year:2019 number:1 pages:153 https://doi.org/10.1016/j.acvdsp.2018.10.339 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 11 2019 1 153 |
| allfieldsGer |
10.1016/j.acvdsp.2018.10.339 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica (DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 DE-627 ger DE-627 rakwb eng 380 VZ 55.82 bkl Montastruc, F. verfasserin aut Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Benevent, J. oth Rousseau, V. oth Montastruc, G. oth Durrieu, G. oth Sommet, A. oth Montastruc, J.L. oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:11 year:2019 number:1 pages:153 https://doi.org/10.1016/j.acvdsp.2018.10.339 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 11 2019 1 153 |
| allfieldsSound |
10.1016/j.acvdsp.2018.10.339 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica (DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 DE-627 ger DE-627 rakwb eng 380 VZ 55.82 bkl Montastruc, F. verfasserin aut Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® 2019transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. Benevent, J. oth Rousseau, V. oth Montastruc, G. oth Durrieu, G. oth Sommet, A. oth Montastruc, J.L. oth Enthalten in Elsevier Masson Guan, Xiangyang ELSEVIER A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier 2021 Amsterdam [u.a.] (DE-627)ELV006385559 volume:11 year:2019 number:1 pages:153 https://doi.org/10.1016/j.acvdsp.2018.10.339 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 11 2019 1 153 |
| language |
English |
| source |
Enthalten in A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier Amsterdam [u.a.] volume:11 year:2019 number:1 pages:153 |
| sourceStr |
Enthalten in A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier Amsterdam [u.a.] volume:11 year:2019 number:1 pages:153 |
| format_phy_str_mv |
Article |
| bklname |
Güterverkehr |
| institution |
findex.gbv.de |
| dewey-raw |
380 |
| isfreeaccess_bool |
false |
| container_title |
A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |
| authorswithroles_txt_mv |
Montastruc, F. @@aut@@ Benevent, J. @@oth@@ Rousseau, V. @@oth@@ Montastruc, G. @@oth@@ Durrieu, G. @@oth@@ Sommet, A. @@oth@@ Montastruc, J.L. @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV006385559 |
| dewey-sort |
3380 |
| id |
ELV045296278 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045296278</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626011026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.acvdsp.2018.10.339</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045296278</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1878-6480(18)30594-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Montastruc, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase®</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benevent, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rousseau, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montastruc, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durrieu, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sommet, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montastruc, J.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Guan, Xiangyang ELSEVIER</subfield><subfield code="t">A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006385559</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:153</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.acvdsp.2018.10.339</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">153</subfield></datafield></record></collection>
|
| author |
Montastruc, F. |
| spellingShingle |
Montastruc, F. ddc 380 bkl 55.82 Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| authorStr |
Montastruc, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV006385559 |
| format |
electronic Article |
| dewey-ones |
380 - Commerce, communications & transportation |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
380 VZ 55.82 bkl Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| topic |
ddc 380 bkl 55.82 |
| topic_unstemmed |
ddc 380 bkl 55.82 |
| topic_browse |
ddc 380 bkl 55.82 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j b jb v r vr g m gm g d gd a s as j m jm |
| hierarchy_parent_title |
A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |
| hierarchy_parent_id |
ELV006385559 |
| dewey-tens |
380 - Commerce, communications & transportation |
| hierarchy_top_title |
A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV006385559 |
| title |
Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| ctrlnum |
(DE-627)ELV045296278 (ELSEVIER)S1878-6480(18)30594-9 |
| title_full |
Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| author_sort |
Montastruc, F. |
| journal |
A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |
| journalStr |
A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
153 |
| author_browse |
Montastruc, F. |
| container_volume |
11 |
| class |
380 VZ 55.82 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Montastruc, F. |
| doi_str_mv |
10.1016/j.acvdsp.2018.10.339 |
| dewey-full |
380 |
| title_sort |
risk of diabetes associated with statins and fibrates and their association: a disproportionality analysis using the who spontaneous reporting database, vigibase® |
| title_auth |
Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| abstract |
Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. |
| abstractGer |
Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. |
| abstract_unstemmed |
Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase® |
| url |
https://doi.org/10.1016/j.acvdsp.2018.10.339 |
| remote_bool |
true |
| author2 |
Benevent, J. Rousseau, V. Montastruc, G. Durrieu, G. Sommet, A. Montastruc, J.L. |
| author2Str |
Benevent, J. Rousseau, V. Montastruc, G. Durrieu, G. Sommet, A. Montastruc, J.L. |
| ppnlink |
ELV006385559 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.acvdsp.2018.10.339 |
| up_date |
2024-07-06T17:08:11.010Z |
| _version_ |
1803850288740696064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045296278</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626011026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.acvdsp.2018.10.339</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001000.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045296278</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1878-6480(18)30594-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Montastruc, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk of diabetes associated with statins and fibrates and their association: A disproportionality analysis using the WHO spontaneous reporting database, Vigibase®</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Relations between hypolipidemic drugs and diabetes are discussed. The aim of our study was to assess the association between diabetes and use of statins or fibrates or their association using the World Health Organization (WHO) global individual case safety reports database, VigiBase®, which records reports from over 130 countries worldwide. We performed a disproportionality analysis including all reports until the 31st December 2017 to measure the risk of reporting “new onset of diabetes” compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for statins, fibrates and their association. The likelihood that diabetes resulted from statin-fibrate pharmacodynamic interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and excluding reports with drugs known to induce hyperglycaemia or diabetes. We identified 7633 cases of diabetes (mainly with atorvastatin) and 169,690 non-cases among reports with statins alone, 189 cases (mainly with fenofibrate) and 18,960 non-cases among reports with fibrates alone with 60 cases and 3,187 among reports with the combination statin-fibrates. Statin use alone was associated with an increase in the ROR of diabetes (ROR=1.75 [1.72–1.78]), but not with fibrate use alone (ROR=0.76 [0.71–0.82]). The combination of statin+fibrate was associated with an increase in the ROR of diabetes (ROR=1.46 [1.28–1.67]) but was not significant to support a DDI. Similar results were found in sensitivity analyses. Using the WHO pharmacovigilance database, our study confirmed the signal of diabetes with statins but failed to find any potential signal with fibrates alone and did not suggest a pharmacodynamic DDI with the use of statin+fibrate.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benevent, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rousseau, V.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montastruc, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durrieu, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sommet, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montastruc, J.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Guan, Xiangyang ELSEVIER</subfield><subfield code="t">A behaviorally-integrated individual-level state-transition model that can predict rapid changes in evacuation demand days earlier</subfield><subfield code="d">2021</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV006385559</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:153</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.acvdsp.2018.10.339</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">153</subfield></datafield></record></collection>
|
| score |
7.400199 |